solute carrier family 38 member 2Genealiases: ATA2 · PRO1068 · SAT2 · SNAT2
Q-omics provides the consensus-scored SLC38A2 profile across patient tissues and cancer cell-line models. SLC38A2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SLC38A2 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, SLC38A2 RNA expression shows 20,289 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and HNSC as cancer lineages where SLC38A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC38A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC38A2 survival associations across molecular data types. SLC38A2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC38A2 RNA expression–survival associations across cancer types. High SLC38A2 expression shows unfavorable associations in UVM, MESO, STAD, PAAD and KIRP, but favorable associations in UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for SLC38A2 RNA expression.
This table summarizes SLC38A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SLC38A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC38A2 shows lower tumor expression in THCA and LIHC and higher tumor expression in HNSC, KIRC, KIRP and BLCA. The HNSC box plot shows higher SLC38A2 RNA expression in tumor versus normal tissue (log2 FC = +1.188, t-test p < 0.001).
This table shows molecular features associated with SLC38A2 in patient tissues and cancer cell lines. In patient samples, SLC38A2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC38A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
